Nefropatía lúpica: una puesta al día

Colmán, 2016, Manifestaciones clínicas y laboratoriales en el lupus eritematoso sistémico-LES, Mem Inst Investig Cienc Salud., 14, 94 Borchers, 2010, The geoepidemiology of systemic lupus erythematosus, Autoimmun Rev., 9, A277, 10.1016/j.autrev.2009.12.008 Fernández-Ávila, 2019, Prevalence of systemic lupus erythematosus in Colombia: Data from the national health registry 2012-2016, Lupus., 28, 1273, 10.1177/0961203319864168 Almaani, 2017, Update on lupus nephritis, Clin J Am Soc Nephrol., 12, 825, 10.2215/CJN.05780616 Fernández-Nebro, 2012, Systemic lupus erythematosus: Genomics, mechanisms, and therapies, Clin Dev Immunol., 2012, 926931, 10.1155/2012/926931 Cervera, 2006, European working party on systemic lupus erythematosus Systemic lupus erythematosus in Europe at the change of the millennium: Lessons from the “Euro-Lupus Project”, Autoimmun Rev., 5, 180, 10.1016/j.autrev.2005.06.004 Pinto, 1997, Lupus eritematoso sistémico: análisis del comportamiento clínico en una población de Medellín, Rev Colomb Reumatol., 4, 170 Ramírez-Gómez, 1998, Lupus eritematoso sistémico en niños, Rev Colomb Reumatol., 5, 11 Choi, 2012, The pathogenesis of systemic lupus erythematosus-an update, Curr Opin Immunol., 24, 651, 10.1016/j.coi.2012.10.004 Mccarty, 1995, Incidence of systemic lupus erythematosus race and gender differences, Arthritis Rheum., 38, 1260, 10.1002/art.1780380914 Molokhia, 2003, Relation of risk of systemic lupus erythematosus to west African admixture in a Caribbean population, Hum Genet., 112, 310, 10.1007/s00439-002-0883-3 Danchenko, 2006, Epidemiology of systemic lupus erythematosus: A comparison of worldwide disease burden, Lupus., 15, 308, 10.1191/0961203306lu2305xx Korbett, 2007, Severe lupus nephritis: Racial differences in presentation and outcome, J Am Soc Nephrol., 18, 244, 10.1681/ASN.2006090992 Alarcón, 1998, Systemic lupus erythematosus in three ethnic groups: II Features predictive of disease activity early in its course, Arthritis Rheum., 41, 1173, 10.1002/1529-0131(199807)41:7<1173::AID-ART5>3.0.CO;2-A Peralta-Ramírez, 2004, The effects of daily stress and stressful life events on the clinical symptomatology of patients with lupus erythematosus, Psychosom Med., 66, 788, 10.1097/01.psy.0000133327.41044.94 Reveille, 1998, Systemic lupus erythematosus in three ethnic groups: I. The effects of HLA class II C4, and CR1 alleles, socioeconomic factors, and ethnicity at disease onset, Arthritis Rheum., 41, 1161, 10.1002/1529-0131(199807)41:7<1161::AID-ART4>3.0.CO;2-K Ortega, 2010, Review: Lupus nephritis: Pathologic features, epidemiology and guide to therapeutic decisions, Lupus., 19, 567, 10.1177/0961203309358187 Gómez-Puerta, 2015, Racial and ethnic differences in mortality and cardiovascular events among patients with end-stage renal disease due to lupus nephritis, Arthritis Care Res (Hoboken)., 67, 1453, 10.1002/acr.22562 Larsen, 2013, Apolipoprotein L1 risk variants associate with systemic lupus erythematosus-associated collapsing glomerulopathy, J Am Soc Nephrol., 24, 722, 10.1681/ASN.2012121180 Iwamoto, 2017, Genetics of human lupus nephritis, Clin Immunol., 185, 32, 10.1016/j.clim.2016.09.012 Lee, 2015, Association between the functional ITGAM rs1143679 G/A polymorphism and systemic lupus erythematosus/lupus nephritis or rheumatoid arthritis: An update meta-analysis, Rheumatol Int., 35, 815, 10.1007/s00296-014-3156-2 Monroe, 2015, Genetics of lupus nephritis: Clinical implications, Semin Nephrol., 35, 396, 10.1016/j.semnephrol.2015.08.002 Yung, 2012, Autoantibodies and resident renal cells in the pathogenesis of lupus nephritis: Getting to know the unknown, Clin Dev Immunol., 2012, 139365, 10.1155/2012/139365 Apostolidis, 2011, The dysregulation of cytokine networks in systemic lupus erythematosus, J Interferon Cytokine Res., 31, 769, 10.1089/jir.2011.0029 Anders, 2016, A pathophysiology-based approach to the diagnosis and treatment of lupus nephritis, Kidney Int., 90, 493, 10.1016/j.kint.2016.05.017 Petri, 2008, Systemic lupus international collaborating clinics renal activity/response exercise: Development of a renal activity score and renal response index, Arthritis Rheum., 58, 1784, 10.1002/art.23456 Borchers, 2012, Lupus nephritis: A critical review, Autoimmun Rev., 12, 174, 10.1016/j.autrev.2012.08.018 Bajema, 2018, Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: Clarification of definitions, and modified National Institutes of Health activity and chronicity indices, Kidney Int., 93, 789, 10.1016/j.kint.2017.11.023 Tan, 1982, The 1982 revised criteria for classification systemic lupus erythematosus, Arthritis Rheum., 25, 1271, 10.1002/art.1780251101 Bertsias, 2012, Joint European League Against Rheumatism and European Association-European Dialysis and Transplant Association recommendations for the management of adult and pediatric lupus nephritis, Ann Rheum Dis., 71, 1771, 10.1136/annrheumdis-2012-201940 Petri, 2012, Derivation and validation of the Systemic Lupus Erythematosus International Collaborating Clinics classification criteria for systemic lupus erythematosus, Arthritis Rheum., 64, 2677, 10.1002/art.34473 Bihl, 2006, Kidney biopsy in lupus nephritis: Look before you leap, Nephrol Dial Transplant., 21, 1749, 10.1093/ndt/gfl159 Mittal, 2005, The role of kidney biopsy in the management of lupus nephritis, Curr Opin Nephrol Hypertens., 14, 1, 10.1097/00041552-200501000-00002 Parikh, 2015, The kidney biopsy in lupus nephritis: Past, present, and future, Semin Nephrol., 35, 465, 10.1016/j.semnephrol.2015.08.008 Weening, 2004, The classification of glomerulonephritis in systemic lupus erythematosus revisited, J Am Soc Nephrol., 15, 241, 10.1097/01.ASN.0000108969.21691.5D Wakasugi, 2012, Frequency of class iii and iv nephritis in systemic lupus erythematosus without clinical renal involvement: An analysis of predictive measures, J Rheumatol., 39, 79, 10.3899/jrheum.110532 Parikh, 2020, Update on lupus nephritis: Core curriculum 2020, Am J Kidney Dis., 76, 265, 10.1053/j.ajkd.2019.10.017 Fanouriakis, 2020, 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis, Ann Rheum Dis., 79, 713, 10.1136/annrheumdis-2020-216924 Soliman, 2017, Lupus nephritis biomarkers, Clin Immunol., 185, 10, 10.1016/j.clim.2016.08.001 Davidson, 2019, Lupus nephritis: Challenges and progress, Curr Opin Rheumatol., 31, 682, 10.1097/BOR.0000000000000642 Dall’Era, 2017, Treatment of lupus nephritis: Current paradigms and emerging strategies, Curr Opin Rheumatol., 29, 241, 10.1097/BOR.0000000000000381 Houssiau, 2002, Immunosuppressive therapy in lupus nephritis: The Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide, Arthritis Rheum., 46, 2121, 10.1002/art.10461 Dedong, 2019, Analysis of interleukin-17 and interleukin-23 for estimating disease activity and predicting the response to treatment in active lupus nephritis patients, Immunol Lett., 210, 33, 10.1016/j.imlet.2019.04.002 Parikh, 2016, Current and emerging therapies for lupus nephritis, J Am Soc Nephrol., 27, 2929, 10.1681/ASN.2016040415 Rovin, 2021, Efficacy and safety of voclosporin versus placebo for lupus nephritis (Aurora 1): A double-blind, randomised, multicentre, placebo-controlled, phase 3 trial, Lancet., 397, 2070, 10.1016/S0140-6736(21)00578-X Yo, 2019, Management of refractory lupus nephritis: Challenges and solutions, Open Access Rheumatol., 11, 179, 10.2147/OARRR.S166303 Lei, 2021, B-cell depletion or belimumab or voclosporin for lupus nephritis?, Curr Opin Nephrol Hypertens., 30, 237, 10.1097/MNH.0000000000000662 Furie, 2020, Two-year, randomized, controlled trial of belimumab in lupus nephritis, N Engl J Med., 383, 1117, 10.1056/NEJMoa2001180 Condon, 2013, Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids, Ann Rheum Dis., 72, 1280, 10.1136/annrheumdis-2012-202844 Abujam, 2013, Urinary CXCL-10/IP-10 and MCP-1 as markers to assess activity of lupus nephritis, Lupus., 22, 614, 10.1177/0961203313484977 Dooley, 1997, Cyclophosphamide therapy for lupus nephritis: Poor renal survival in black Americans, Kidney Int., 51, 1188, 10.1038/ki.1997.162 Mok, 2006, Therapeutic options for resistant lupus nephritis, Semin Arthritis Rheum., 36, 71, 10.1016/j.semarthrit.2006.04.008 Mok, 2010, Biomarkers for lupus nephritis: A critical appraisal, J Biomed Biotechnol., 2010, 638413, 10.1155/2010/638413 Faurschou, 2006, Prognostic factors in lupus nephritis: Diagnostic and therapeutic delay increases the risk of terminal renal failure, J Rheumatol., 33, 1563